Assembly Biosciences Inc. (NASDAQ: ASMB) is -29.09% lower on its value in year-to-date trading and has touched a low of $4.01 and a high of $27.84 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ASMB stock was last observed hovering at around $4.38 in the last trading session, with the day’s loss setting it -0.09% off its average median price target of $13.00 for the next 12 months. It is also 71.4% off the consensus price target high of $15.00 offered by 6 analysts, but current levels are 28.5% higher than the price target low of $6.00 for the same period.
Currently trading at $4.29, the stock is -1.22% and -9.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.97 million and changing -2.05% at the moment leaves the stock -61.01% off its SMA200. ASMB registered -76.71% loss for a year compared to 6-month loss of -71.03%. The firm has a 50-day simple moving average (SMA 50) of $4.5082 and a 200-day simple moving average (SMA200) of $6.7962.
The stock witnessed a -4.67% gain in the last 1 month and extending the period to 3 months gives it a -22.98%, and is -1.83% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.03% over the week and 4.09% over the month.
Assembly Biosciences Inc. (ASMB) has around 139 employees, a market worth around $174.69M and $79.10M in sales. Profit margin for the company is -78.60%. Distance from 52-week low is 6.98% and -84.59% from its 52-week high.
Assembly Biosciences Inc. (ASMB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Assembly Biosciences Inc. (ASMB) is a “Overweight”. 6 analysts offering their recommendations for the stock have an average rating of 2.00, where 2 rate it as a Hold and 1 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Assembly Biosciences Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.79 with sales reaching $2.51M over the same period.The EPS is expected to grow by 52.80% this year, but quarterly earnings will post -88.80% year-over-year.
Assembly Biosciences Inc. (ASMB) Top Institutional Holders
166 institutions hold shares in Assembly Biosciences Inc. (ASMB), with 641.39k shares held by insiders accounting for 1.68% while institutional investors hold 69.85% of the company’s shares. The shares outstanding are 35.19M, and float is at 31.49M with Short Float at 12.80%. Institutions hold 68.68% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 2.78 million shares valued at $16.84 million. The investor’s holdings represent 6.95% of the ASMB Shares outstanding. As of Dec 30, 2020, the second largest holder is Armistice Capital, LLC with 2.62 million shares valued at $15.88 million to account for 6.55% of the shares outstanding. The other top investors are Satter Management Company, LP which holds 2.23 million shares representing 5.56% and valued at over $13.48 million, while Consonance Capital Management LP holds 4.92% of the shares totaling 1.97 million with a market value of $11.92 million.
Assembly Biosciences Inc. (ASMB) Insider Activity
A total of 5 insider transactions have happened at Assembly Biosciences Inc. (ASMB) in the last six months, with sales accounting for 2 and purchases happening 3 times. The most recent transaction is an insider sale by Papkoff Jacqueline Sybil, the company’s SVP-CSO Microbiome. SEC filings show that Papkoff Jacqueline Sybil sold 1,297 shares of the company’s common stock on Dec 14 at a price of $6.15 per share for a total of $7983.0. Following the sale, the insider now owns 37364.0 shares.
Assembly Biosciences Inc. disclosed in a document filed with the SEC on Nov 09 that Stamm Luisa M (Chief Medical Officer) sold a total of 4,397 shares of the company’s common stock. The trade occurred on Nov 09 and was made at $5.10 per share for $22404.0. Following the transaction, the insider now directly holds 7603.0 shares of the ASMB stock.
Still, SEC filings show that on Aug 07, McHutchison John G (CEO and President) disposed off 12,151 shares at an average price of $21.80 for $0.26 million. The insider now directly holds 137,849 shares of Assembly Biosciences Inc. (ASMB).
Assembly Biosciences Inc. (ASMB): Who are the competitors?
The company’s main competitors (and peers) include Ironwood Pharmaceuticals Inc. (IRWD) that is trading 10.07% up over the past 12 months. Short interest in the company’s stock has fallen -9.81% from the last report on Apr 14, 2021 to stand at a total of 4.03 million short shares sold with a short interest ratio of 4.69.